← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ossium Health, Inc.
San Francisco, CA
$9,322,632
Total funding
11
Grants
Funding over time
peak $2.7M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,322,632 · 11
By mechanism
R44$4,523,630 · 3
U01$2,989,521 · 1
R43$1,336,576 · 5
R41$472,905 · 2
Investigators at Ossium Health, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury$1,000,000
R44 · FY2025 · AI
Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone Marrow$999,998
R44 · FY2020 · AI
OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome.$928,679
U01 · FY2021 · AI
Novel strategies for storage and recovery of cadaveric bone marrow stem cells$778,661
R44 · FY2020 · HL
Novel strategies for storage and recovery of cadaveric bone marrow stem cells$687,302
R44 · FY2021 · HL
Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone Marrow$682,556
R44 · FY2019 · AI
OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome.$601,224
U01 · FY2019 · AI
OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome.$572,754
U01 · FY2022 · AI
OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome.$494,963
U01 · FY2020 · AI
Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury$375,113
R44 · FY2024 · AI
OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome.$323,360
U01 · FY2018 · AI
Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury$299,998
R43 · FY2020 · AI
Deceased Donor Bone Marrow Salvage and Processing$272,587
R43 · FY2017 · AI
A novel approach to Mesenchymal Stem Cell Transduction$248,452
R41 · FY2021 · HL
Novel Disaccharide-Based Cryopreservation Approach for Stable, -80°C Storage of Stem Cells$239,080
R43 · FY2017 · HL
Novel strategies for storage and recovery of cadaveric bone marrow stem cells$224,961
R43 · FY2018 · HL
Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media$224,453
R41 · FY2021 · GM
A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance$157,465
R43 · FY2020 · AI
A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance$142,485
R43 · FY2021 · AI
OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome.$68,541
U01 · FY2021 · AI